Key takeaways
- Clinical diagnostics is the next test: the ARGO HT/DX instrument heads to FDA review by late 2027, a step beyond academic research.
- On its third-quarter 2026 earnings webcast call, held on Nov. 3, 2026, Alamar Biosciences (ALMR) raised its full-year 2026 revenue guidance to between $121 million and $123 million.
- Biopharmaceutical clients generated 49% of third-quarter revenue, becoming the company's largest customer segment for the first time.
Full-year 2026 revenue guidance increased to $121 million -- $123 million. U.K. Biobank selected NULISA to profile 80,000 samples for neurodegenerative markers.
See the latest quote, chart and news for ALMR.
